Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 8/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767795 | 1.00 | ADRB3 (0.49) | ADRB3ADRB1ADRB2SLC2A1IDO1 | |
| SCHEMBL2879198 | 1.00 | ADRB3 (0.49) | ADRB3ADRB1ADRB2SLC2A1IDO1 | |
| SCHEMBL14038059 | 0.86 | TSHR (0.47) | ADRB3ADRB1ADRB2LMNA | |
| SCHEMBL1560927 | 0.85 | ADRB3 (0.48) | ADRB3ADRB1ADRB2SLC2A1IDO1 | |
| SCHEMBL3917396 | 0.85 | ADRB3 (0.48) | ADRB3ADRB1ADRB2SLC2A1IDO1 | |
| SCHEMBL7107297 | 0.85 | ADRB3 (0.48) | ADRB3ADRB1ADRB2SLC2A1IDO1 | |
| SCHEMBL7105071 | 0.85 | ADRB3 (0.48) | ADRB3ADRB1ADRB2SLC2A1IDO1 | |
| SCHEMBL8098427 | 0.85 | ADRB3 (0.48) | ADRB3ADRB1ADRB2SLC2A1IDO1 | |
| SCHEMBL98267 | 0.85 | ADRB3 (0.48) | ADRB3ADRB1ADRB2SLC2A1IDO1 | |
| SCHEMBL23489604 | 0.83 | ADRB3 (0.47) | ADRB3ADRB1ADRB2SLC2A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114108014-B | Method for synthesizing pinacol by selective electroreduction coupling of active hydrogen-mediated carbonyl compound in water | 天津大学 | 2023-08-11 | — | — | CN | claimed |
| CN-114108014-A | Method for synthesizing pinacol by selective electroreduction coupling of carbonyl compound mediated by active hydrogen in water | 天津大学 | 2022-03-01 | — | — | CN | claimed |
| EP-4709708-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2026-03-18 | — | — | EP | disclosed |
| EP-4588918-A1 | SYNTHESIS OF (S)-1-(1-(3-CHLOROPHENYL)-2-(DIMETHYLAMINO)ETHYL)- 4-(5-MORPHOLINO-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIDIN-2(1H)-ONE | AGV Discovery (FR) | 2025-07-23 | — | — | EP | disclosed |
| US-20250065315-A1 | IRON COMPLEXES FOR ENANTIOSELECTIVE CIS DIHYDROXYLATION OF ALKENES | Laboratory for Synthetic Chemistry and Chemical Biology Limited (CN) | 2025-02-27 | — | — | US | disclosed |
| WO-2024233603-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ICAGEN, LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4308227-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396473-A | Imidazopyridinyl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| CN-112638917-B | Heterocyclic compounds as kinase inhibitors, compositions comprising the same, and methods of use thereof | 捷思英达控股有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-114108014-B | Method for synthesizing pinacol by selective electroreduction coupling of active hydrogen-mediated carbonyl compound in water | 天津大学 | 2023-08-11 | — | — | CN | disclosed |
| US-6103759-A | COMPRISING PURE ENANTIOMERIC FORMS, AS WELL AS ENANTIOMERIC MIXTURES, OF (2-(2-CHLOROPHENYL)-2-HYDROXYETHYL)OXYCARBOXAMIDE; USEFUL FOR TRATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | SK CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| WO-2000009463-A1 | STEREOSELECTIVE RING OPENING REACTIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0934264-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0907635-A1 | HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL | SK Corporation (KR) | 1999-04-14 | — | — | EP | disclosed |
| US-5854283-A | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol | YUKONG LIMITED (KR) | 1998-12-29 | — | — | US | disclosed |
| WO-1998012177-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (JP) | 1998-03-26 | — | — | WO | disclosed |
| EP-0816316-A1 | PROCESS FOR PRODUCING 1,2-ETHANEDIOL DERIVATIVES | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997026241-A1 | HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL | SK CORPORATION (KR) | 1997-07-24 | — | — | WO | disclosed |
| WO-1994025427-A1 | ETHANOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK4 | ADRB3 1664/4885ADRB1 1937/4885ADRB2 2658/4885 |
| US-20250065315-A1 | IRON COMPLEXES FOR ENANTIOSELECTIVE CIS DIHYDROXYLATION OF ALKENES | SQLE, NFE2L2, FECH | ADRB3 1000/4885ADRB1 547/4885ADRB2 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.